Abstract Number: 1374 • ACR Convergence 2022
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
Background/Purpose: Belimumab is the only targeted therapy approved for pediatric systemic lupus erythematosus (pSLE), although use remains limited in children. While clinical trials and studies…Abstract Number: 1429 • ACR Convergence 2022
Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared with the general…Abstract Number: 1546 • ACR Convergence 2022
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry
Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations…Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…Abstract Number: 0031 • ACR Convergence 2021
A New Pharmacostatistical Model to Assess MTX-adherence in RA Patients
Background/Purpose: Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis (RA). While therapeutic adherence is essential to the successful management of the patient, an estimated…Abstract Number: 0101 • ACR Convergence 2021
Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
Background/Purpose: Persons with immune mediated Inflammatory diseases (IMIDs) are at increased risk of developing herpes zoster (HZ) and postherpetic neuralgia. In 2018, CDC recommended a…Abstract Number: 0573 • ACR Convergence 2021
Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
Background/Purpose: In routine care, biosimilar to biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of…Abstract Number: 0588 • ACR Convergence 2021
Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Patients with Rheumatoid Arthritis: Data from the ACR’s RISE Registry
Background/Purpose: Our understanding of how medications such as biologic disease modifying anti-rheumatic drugs and targeted small molecules (b/tsDMARDs) influence disease activity in RA is based…Abstract Number: 0724 • ACR Convergence 2021
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
Background/Purpose: Tanezumab is a humanized monoclonal antibody against nerve growth factor that has been evaluated for relief of chronic osteoarthritis pain by subcutaneous (SC) or…Abstract Number: 0767 • ACR Convergence 2021
Medication Use in Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Black and Hispanic children with pediatric lupus (pSLE) have higher morbidity and mortality, but the extent to which differences in outcomes may be related…Abstract Number: 1121 • ACR Convergence 2021
Association of Healthcare Costs and Utilization with Increasing Severity of Pain in Osteoarthritis Patients: An 18-Year Retrospective Study
Background/Purpose: Osteoarthritis (OA) is a disease with complex pathogenesis, and it is important to understand a patient's level of severity in order to plan and…Abstract Number: 1444 • ACR Convergence 2021
Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) is the first-line treatment in the management of patients with rheumatoid arthritis (RA) due to its good efficacy. However, certain adverse events,…Abstract Number: 1565 • ACR Convergence 2021
Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial
Background/Purpose: Previous analyses in the CANTOS trial demonstrated a benefit of canakinumab (CAN; IL-1β inhibitor) on gout flares. We aimed to quantify the mediating role…Abstract Number: 1659 • ACR Convergence 2021
Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthritis After First Antidepressant Dispensing: Results from the Nationwide DANBIO Database
Background/Purpose: Depression occurs with a prevalence of about 17% (95% confidence interval (CI): 10-24) in patients with RA (1) and both disorders may share common…Abstract Number: 1675 • ACR Convergence 2021
Risk of Malignancy in Patients Treated with Tofacitinib: Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Background/Purpose: Initial reports from “ORAL Surveillance” post-marketing safety trial have suggested that tofacitinib, in comparison with tumor necrosis factor inhibitors (TNFI), may be associated with…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »